BPC-157 is not FDA-approved and not a legal compounding ingredient in the US as of October 2026; a July advisory vote to allow compounding has not become a rule. Everything on this page is a regulatory fact from FDA, Federal Register or WADA records unless a label says otherwise. Last checked October 15, 2026.
For every other peptide, see which peptides are legal in the US. For what BPC-157 was tested for, see the BPC-157 evidence profile, and for how it differs from TB-500, which got the same 8-6 vote, see BPC-157 vs TB-500.
New trials, FDA changes and side-effect reports, written in plain English. Every result says whether it was tested in people or in animals.
5 of 8 steps are done. The three that would make it a lawful compounding ingredient have not started.
FDA listed BPC-157 as a 503A substance that may pose significant safety risks, citing immunogenicity and peptide impurities.
SourceA Federal Register notice set a July 23 advisory meeting on BPC-157 for ulcerative colitis.
SourceBy April 22, FDA's safety-risk page listed BPC-157 as 'nominated but withdrawn', which is no category at all. FDA's own review went ahead anyway.
SourceFDA reviewers concluded the criteria weigh against adding BPC-157 to the list.
SourceThe Pharmacy Compounding Advisory Committee voted 8 to 6, 1 abstaining, to recommend it (reported).
SourceFDA would publish a proposed rule in the Federal Register. None as of October 15, 2026.
Anyone can comment on a proposed rule before FDA decides.
Only a final rule adding BPC-157 to 21 CFR 216.23(a) makes it a lawful 503A ingredient.
Yes, but the FDA did not clear it. BPC-157 left Category 2 because the two groups that nominated it, Wells Pharmacy Network and LDT Health Solutions, withdrew their nominations. By April 22, 2026 FDA listed it under "nominated but withdrawn".
Category 2 was a warning: FDA placed BPC-157 there on September 29, 2023, citing possible immune reactions and impurities in the peptide. Category 1 is the protected group: under FDA's interim policy, the agency does not intend to act against pharmacies that compound a Category 1 substance while it is reviewed. A withdrawn nomination lands in neither group, so leaving Category 2 gave pharmacies no new permission.
FDA then reviewed BPC-157 on its own initiative, for ulcerative colitis only, and sent it to its advisory committee. The human studies its reviewers had to go on are listed one by one in the BPC-157 human studies ledger.
No, not under section 503A as of October 2026. A 503A pharmacy needs a lawful route for each bulk ingredient, and BPC-157 fails every one.
| Route a 503A pharmacy can use | Does BPC-157 qualify? | Source |
|---|---|---|
| A USP or NF monograph for the ingredient | No. There is no USP monograph, and BPC-157 is not in the European, Japanese or International Pharmacopoeia. | FDA briefing document, May 2026 |
| A component of an FDA-approved drug | No. FDA found no approved BPC-157 product in any country. | FDA briefing document, May 2026 |
| Listed on the 503A bulks list, 21 CFR 216.23(a) | No. The list holds Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide. | eCFR, as of October 1, 2026 |
| Category 1 under the interim policy, where FDA does not intend to act while it reviews | No. FDA's May 14, 2026 list has BPC-157 in no category. | FDA 503A categories list |
| Category 2, significant safety risks (a block, not a route) | No longer. Moved to "nominated but withdrawn" by April 22, 2026. | FDA Category 2 page |
| Advisory committee recommendation | Yes, 8 to 6, but a recommendation does not change any of the rows above. | RAPS and McDermott, July 2026 |
No. There is no USP monograph, and BPC-157 is not in the European, Japanese or International Pharmacopoeia.
FDA briefing document, May 2026No. FDA found no approved BPC-157 product in any country.
FDA briefing document, May 2026No. The list holds Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester and thymol iodide.
eCFR, as of October 1, 2026No. FDA's May 14, 2026 list has BPC-157 in no category.
FDA 503A categories listNo longer. Moved to "nominated but withdrawn" by April 22, 2026.
FDA Category 2 pageYes, 8 to 6, but a recommendation does not change any of the rows above.
RAPS and McDermott, July 2026How approved, compounded and research-only peptides differ in testing and oversight: pharma vs compounded vs research-use-only peptides.
The committee voted 8 to 6, with 1 abstaining, to recommend adding BPC-157 to the 503A bulks list on July 23, 2026. FDA's own staff had recommended against it.
FDA's review, dated May 11, 2026, concluded that "a balancing of the criteria weighs against" listing BPC-157. Regulatory fact
There is no date. To make BPC-157 a lawful 503A ingredient, FDA has to publish a proposed rule in the Federal Register, take public comments and then publish a final rule adding it to 21 CFR 216.23(a). As of October 15, 2026, no proposed rule naming BPC-157 had appeared, and the list still held the same six substances.
The law firm McDermott wrote in July 2026 that a proposed rule could come in late 2026 or 2027, and that the full process could take several years. That is a forecast, not an FDA statement. FDA has also scheduled a committee review of GHK-Cu, another peptide, before the end of February 2027.
We recheck the FDA category lists, the Federal Register and 21 CFR 216.23 every week and date each change in the changelog below.
This page covers federal drug rules for products and pharmacies. It does not cover personal possession, state law or import rules; ask a lawyer about those.
Ask where the vial comes from. With no lawful 503A route, the product is either compounded outside the rules or bought as a research chemical.
FDA reads intended use from labeling, advertising and how a product is sold (21 CFR 201.128), so the label alone does not decide what the product is.
A prescription does not make an ingredient eligible for 503A compounding. The ingredient still needs one of the routes in the table above.
On August 24, 2026 FDA sent warning letters to five sellers of research-use-only peptides. The letters named other peptides, such as retatrutide and tesamorelin, not BPC-157. FDA counted dosing guidance, reconstitution calculators and bacteriostatic water sold next to the vials as evidence the products were meant for people. Reported by Arent Fox Schiff, Sep 18, 2026 The two letters that do name BPC-157, from 2021 and 2023, are in the table of FDA warning letters to peptide sellers.
Yes. The World Anti-Doping Agency names BPC-157 under S0, non-approved substances, on the 2026 Prohibited List. S0 covers any substance with no approval from a government health authority for human use, and it applies in and out of competition. A research-use-only label makes no difference to a tested athlete. Regulatory fact
The list section and wording for TB-500 and every other peptide on staate are in which peptides are banned in sport.
Is BPC-157 legal in Australia, Canada, the UK or New Zealand? See peptide warnings by country. How we grade and label evidence: editorial policy. What BPC-157 was tested for in rats and people: peptides for healing and recovery.
Page published. Checked FDA's Category 2 page (current April 22, 2026), the 503A categories list (May 14, 2026), 21 CFR 216.23 as of October 1, 2026, the Federal Register and the PCAC meeting page (current August 6, 2026). No proposed rule found.
A proposed rule, a final rule or a change to FDA's category lists changes this page. staate Daily covers each change with the FDA source linked. Free.